Apollomics Announces Preliminary Data Of Vebreltinib In Patients With Non-CNS MET Fusion Solid Tumors From Phase 2 SPARTA Trial Showing 43% Objective Response Rate
Portfolio Pulse from Benzinga Newsdesk
Apollomics announced preliminary data from its Phase 2 SPARTA trial, showing a 43% objective response rate for Vebreltinib in patients with non-CNS MET fusion solid tumors.
August 13, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apollomics announced promising preliminary data from its Phase 2 SPARTA trial, showing a 43% objective response rate for Vebreltinib in patients with non-CNS MET fusion solid tumors.
The positive preliminary data from the Phase 2 SPARTA trial is likely to boost investor confidence in Apollomics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100